215 related articles for article (PubMed ID: 20571544)
1. Neonatal gene therapy of glycogen storage disease type Ia using a feline immunodeficiency virus-based vector.
Grinshpun A; Condiotti R; Waddington SN; Peer M; Zeig E; Peretz S; Simerzin A; Chou J; Pann CJ; Giladi H; Galun E
Mol Ther; 2010 Sep; 18(9):1592-8. PubMed ID: 20571544
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of helper-dependent adenovirus vector-mediated gene therapy in murine glycogen storage disease type Ia.
Koeberl DD; Sun B; Bird A; Chen YT; Oka K; Chan L
Mol Ther; 2007 Jul; 15(7):1253-8. PubMed ID: 17505475
[TBL] [Abstract][Full Text] [Related]
3. Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia.
Koeberl DD; Sun BD; Damodaran TV; Brown T; Millington DS; Benjamin DK; Bird A; Schneider A; Hillman S; Jackson M; Beaty RM; Chen YT
Gene Ther; 2006 Sep; 13(17):1281-9. PubMed ID: 16672983
[TBL] [Abstract][Full Text] [Related]
4. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer.
Ghosh A; Allamarvdasht M; Pan CJ; Sun MS; Mansfield BC; Byrne BJ; Chou JY
Gene Ther; 2006 Feb; 13(4):321-9. PubMed ID: 16195703
[TBL] [Abstract][Full Text] [Related]
5. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.
Lee YM; Pan CJ; Koeberl DD; Mansfield BC; Chou JY
Mol Genet Metab; 2013 Nov; 110(3):275-80. PubMed ID: 23856420
[TBL] [Abstract][Full Text] [Related]
6. Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector.
Luo X; Hall G; Li S; Bird A; Lavin PJ; Winn MP; Kemper AR; Brown TT; Koeberl DD
Mol Ther; 2011 Nov; 19(11):1961-70. PubMed ID: 21730973
[TBL] [Abstract][Full Text] [Related]
7. Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy.
Lee YM; Jun HS; Pan CJ; Lin SR; Wilson LH; Mansfield BC; Chou JY
Hepatology; 2012 Nov; 56(5):1719-29. PubMed ID: 22422504
[TBL] [Abstract][Full Text] [Related]
8. Sustained hepatic and renal glucose-6-phosphatase expression corrects glycogen storage disease type Ia in mice.
Sun MS; Pan CJ; Shieh JJ; Ghosh A; Chen LY; Mansfield BC; Ward JM; Byrne BJ; Chou JY
Hum Mol Genet; 2002 Sep; 11(18):2155-64. PubMed ID: 12189168
[TBL] [Abstract][Full Text] [Related]
9. An evolutionary approach to optimizing glucose-6-phosphatase-α enzymatic activity for gene therapy of glycogen storage disease type Ia.
Zhang L; Cho JH; Arnaoutova I; Mansfield BC; Chou JY
J Inherit Metab Dis; 2019 May; 42(3):470-479. PubMed ID: 30714174
[TBL] [Abstract][Full Text] [Related]
10. AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia.
Koeberl DD; Pinto C; Sun B; Li S; Kozink DM; Benjamin DK; Demaster AK; Kruse MA; Vaughn V; Hillman S; Bird A; Jackson M; Brown T; Kishnani PS; Chen YT
Mol Ther; 2008 Apr; 16(4):665-72. PubMed ID: 18362924
[TBL] [Abstract][Full Text] [Related]
11. Emerging roles of autophagy in hepatic tumorigenesis and therapeutic strategies in glycogen storage disease type Ia: A review.
Cho JH; Weinstein DA; Lee YM
J Inherit Metab Dis; 2021 Jan; 44(1):118-128. PubMed ID: 32474930
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumor-developing stage.
Cho JH; Lee YM; Starost MF; Mansfield BC; Chou JY
J Inherit Metab Dis; 2019 May; 42(3):459-469. PubMed ID: 30637773
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for type I glycogen storage diseases.
Chou JY; Mansfield BC
Curr Gene Ther; 2007 Apr; 7(2):79-88. PubMed ID: 17430128
[TBL] [Abstract][Full Text] [Related]
14. Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors.
Kim GY; Lee YM; Kwon JH; Cho JH; Pan CJ; Starost MF; Mansfield BC; Chou JY
Mol Genet Metab; 2017 Mar; 120(3):229-234. PubMed ID: 28096054
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy using a novel G6PC-S298C variant enhances the long-term efficacy for treating glycogen storage disease type Ia.
Zhang L; Lee C; Arnaoutova I; Anduaga J; Starost MF; Mansfield BC; Chou JY
Biochem Biophys Res Commun; 2020 Jun; 527(3):824-830. PubMed ID: 32430177
[TBL] [Abstract][Full Text] [Related]
16. In Vivo Zinc Finger Nuclease-mediated Targeted Integration of a Glucose-6-phosphatase Transgene Promotes Survival in Mice With Glycogen Storage Disease Type IA.
Landau DJ; Brooks ED; Perez-Pinera P; Amarasekara H; Mefferd A; Li S; Bird A; Gersbach CA; Koeberl DD
Mol Ther; 2016 Apr; 24(4):697-706. PubMed ID: 26865405
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of growth failure and partial reversal with gene therapy in murine and canine Glycogen Storage Disease type Ia.
Brooks ED; Little D; Arumugam R; Sun B; Curtis S; Demaster A; Maranzano M; Jackson MW; Kishnani P; Freemark MS; Koeberl DD
Mol Genet Metab; 2013 Jun; 109(2):161-70. PubMed ID: 23623482
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type Ia.
Demaster A; Luo X; Curtis S; Williams KD; Landau DJ; Drake EJ; Kozink DM; Bird A; Crane B; Sun F; Pinto CR; Brown TT; Kemper AR; Koeberl DD
Hum Gene Ther; 2012 Apr; 23(4):407-18. PubMed ID: 22185325
[TBL] [Abstract][Full Text] [Related]
19. In search of proof-of-concept: gene therapy for glycogen storage disease type Ia.
Koeberl DD
J Inherit Metab Dis; 2012 Jul; 35(4):671-8. PubMed ID: 22310927
[TBL] [Abstract][Full Text] [Related]
20. Correction of metabolic abnormalities in a mouse model of glycogen storage disease type Ia by CRISPR/Cas9-based gene editing.
Arnaoutova I; Zhang L; Chen HD; Mansfield BC; Chou JY
Mol Ther; 2021 Apr; 29(4):1602-1610. PubMed ID: 33359667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
